Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Daiichi Sankyo Company ( (JP:4568) ) has issued an update.
Daiichi Sankyo released consolidated financial reference data for fiscal year 2025, detailing its profit or loss statement, core operating profit adjustments, and revenue performance across global products and business units. The materials also cover the company’s financial position, cash flows, capital expenditures, key R&D pipeline information, and historical and quarterly data, providing stakeholders with a comprehensive view of its operational and research profile.
The most recent analyst rating on (JP:4568) stock is a Buy with a Yen3100.00 price target. To see the full list of analyst forecasts on Daiichi Sankyo Company stock, see the JP:4568 Stock Forecast page.
More about Daiichi Sankyo Company
Daiichi Sankyo Co., Ltd. is a Japan-based pharmaceutical company listed on the Tokyo Stock Exchange under ticker 4568. It develops and markets innovative pharmaceuticals and related healthcare products, with a global focus on prescription medicines and research-driven drug pipelines.
YTD Price Performance: -21.42%
Average Trading Volume: 8,750,053
Technical Sentiment Signal: Sell
Current Market Cap: Yen4839.1B
See more insights into 4568 stock on TipRanks’ Stock Analysis page.